Left atrial appendage occlusion with the AMPLATZER Amulet device: one-year follow-up from the prospective global Amulet observational registry

EuroIntervention 2018;14:e590-e597 published online May 2018 online publish-ahead-of-print May 2018 published online e-edition August 2018. DOI: 10.4244/EIJ-D-18-00344

Ulf Landmesser
Ulf Landmesser1*, MD; Claudio Tondo2, MD, PhD; John Camm3, MD; Hans-Christoph Diener4, MD, PhD; Vince Paul5, MD; Boris Schmidt6, MD; Magnus Settergren7, MD, PhD; Emmanuel Teiger8, MD, PhD; Jens Erik Nielsen-Kudsk9, MD, DMSc; David Hildick-Smith10, MD; on behalf of the Amulet Observational Study Investigators
1. Department of Cardiology, Charité – Universitätsmedizin Berlin, Berlin Institute of Health (BIH), Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Partner Site Berlin, Berlin, Germany; 2. Heart Rhythm Centre at Monzino Cardiac Center, IRCCS, Depa

Aims: Left atrial appendage occlusion (LAAO) is a stroke prevention therapy for patients with non-valvular atrial fibrillation (AF). This study reports one-year outcomes from patients enr

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

antithrombotic treatmentbleedingdeathlaa closurestroke
Interventions for strokeLAA closure
Read next article
Will SPYRAL HTN-ON MED change my practice? SPYRAL HTN-ON MED: a prospective, randomised, sham-controlled trial on renal denervation in the presence of antihypertensive medications

Latest news